Print

Medtronic, Inc. (MDT) Release: First Patient Enrolled in Medtronic-Supported Head-to-Head Clinical Trial Comparing Cryoballoon Ablation to RF Ablation for Paroxysmal Atrial Fibrillation  
1/24/2012 7:47:36 AM

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced the first patient was enrolled in the FIRE AND ICE clinical trial, which is a prospective, randomized, multinational head-to-head clinical trial comparing the long-term safety, effectiveness and ease of use of the Medtronic Arctic Front® Cardiac CryoAblation System compared to the Biosense Webster CARTO® System Guided THERMOCOOL® Catheter to treat patients with symptomatic paroxysmal atrial fibrillation. Results from the trial, expected in 2014, could potentially impact atrial fibrillation treatment guidelines by providing further clinical evidence regarding the benefits of the Arctic Front system in treating a largely underserved patient population.
//-->